Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: Results of a phase IIb double-blind study of salbutamol

Francesco Danilo Tiziano, Rosa Lomastro, Emanuela Abiusi, Maria Barbara Pasanisi, Lorena Di Pietro, Stefania Fiori, Giovanni Baranello, Corrado Angelini, Gianni Sorarù, Alessandra Gaiani, Tiziana Mongini, Liliana Vercelli, Eugenio Mercuri, Gessica Vasco, Marika Pane, Giuseppe Vita, Gianluca Vita, Sonia Messina, Roberta Petillo, Luigia PassamanoLuisa Politano, Angela Campanella, Renato Mantegazza, Lucia Morandi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, due to the loss of function of the survival motor neuron (SMN1) gene. The first treatment for the condition, recently approved, is based on the reduction of exon 7 skipping in mRNAs produced by a highly homologous gene (SMN2). The primary objective of the present study was to evaluate the applicability of the dosage of SMN gene produts in blood, as biomarker for SMA, and the safety of oral salbutamol, a beta2-adrenergic agonist modulating SMN2 levels. Methods: We have performed a 1-year multicentre, double-blind, placebo-controlled study with salbutamol in 45 adult patients with SMA. Patients assumed 4 mg of salbutamol or placebo/three times a day. Molecular tests were SMN2 copy number, SMN transcript and protein levels. We have also explored the clinical effect, by the outcome measures available at the time of study design. Results: Thirty-six patients completed the study. Salbutamol was safe and well tolerated. We observed a significant and progressive increase in SMN2 full-length levels in peripheral blood of the salbutamol-treated patients (p<0.00001). The exploratory analysis of motor function showed an improvement in most patients. Conclusions: Our data demonstrate safety and molecular efficacy of salbutamol. We provide the first longitudinal evaluation of SMN levels (both transcripts and protein) in placebo and in response to a compound modulating the gene expression: SMN transcript dosage in peripheral blood is reliable and may be used as pharmacodynamic marker in clinical trials with systemic compounds modifying SMN2levels. Trial registration number: EudraCT no. 2007-001088-32.

Original languageEnglish
JournalJournal of Medical Genetics
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Spinal Muscular Atrophy
Albuterol
Double-Blind Method
Biomarkers
Placebos
Adrenergic beta-2 Receptor Agonists
Safety
Time and Motion Studies
Gene Dosage
Motor Neurons
Genes
Exons
Proteins
Outcome Assessment (Health Care)
Clinical Trials
Gene Expression
Messenger RNA

Keywords

  • double-blind clinical trial
  • real-time PCR
  • salbutamol
  • spinal muscular atrophy

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy : Results of a phase IIb double-blind study of salbutamol. / Tiziano, Francesco Danilo; Lomastro, Rosa; Abiusi, Emanuela; Pasanisi, Maria Barbara; Di Pietro, Lorena; Fiori, Stefania; Baranello, Giovanni; Angelini, Corrado; Sorarù, Gianni; Gaiani, Alessandra; Mongini, Tiziana; Vercelli, Liliana; Mercuri, Eugenio; Vasco, Gessica; Pane, Marika; Vita, Giuseppe; Vita, Gianluca; Messina, Sonia; Petillo, Roberta; Passamano, Luigia; Politano, Luisa; Campanella, Angela; Mantegazza, Renato; Morandi, Lucia.

In: Journal of Medical Genetics, 01.01.2018.

Research output: Contribution to journalArticle

Tiziano, FD, Lomastro, R, Abiusi, E, Pasanisi, MB, Di Pietro, L, Fiori, S, Baranello, G, Angelini, C, Sorarù, G, Gaiani, A, Mongini, T, Vercelli, L, Mercuri, E, Vasco, G, Pane, M, Vita, G, Vita, G, Messina, S, Petillo, R, Passamano, L, Politano, L, Campanella, A, Mantegazza, R & Morandi, L 2018, 'Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: Results of a phase IIb double-blind study of salbutamol', Journal of Medical Genetics. https://doi.org/10.1136/jmedgenet-2018-105482
Tiziano, Francesco Danilo ; Lomastro, Rosa ; Abiusi, Emanuela ; Pasanisi, Maria Barbara ; Di Pietro, Lorena ; Fiori, Stefania ; Baranello, Giovanni ; Angelini, Corrado ; Sorarù, Gianni ; Gaiani, Alessandra ; Mongini, Tiziana ; Vercelli, Liliana ; Mercuri, Eugenio ; Vasco, Gessica ; Pane, Marika ; Vita, Giuseppe ; Vita, Gianluca ; Messina, Sonia ; Petillo, Roberta ; Passamano, Luigia ; Politano, Luisa ; Campanella, Angela ; Mantegazza, Renato ; Morandi, Lucia. / Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy : Results of a phase IIb double-blind study of salbutamol. In: Journal of Medical Genetics. 2018.
@article{a49a293f38594659b1156756beca8ca0,
title = "Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: Results of a phase IIb double-blind study of salbutamol",
abstract = "Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, due to the loss of function of the survival motor neuron (SMN1) gene. The first treatment for the condition, recently approved, is based on the reduction of exon 7 skipping in mRNAs produced by a highly homologous gene (SMN2). The primary objective of the present study was to evaluate the applicability of the dosage of SMN gene produts in blood, as biomarker for SMA, and the safety of oral salbutamol, a beta2-adrenergic agonist modulating SMN2 levels. Methods: We have performed a 1-year multicentre, double-blind, placebo-controlled study with salbutamol in 45 adult patients with SMA. Patients assumed 4 mg of salbutamol or placebo/three times a day. Molecular tests were SMN2 copy number, SMN transcript and protein levels. We have also explored the clinical effect, by the outcome measures available at the time of study design. Results: Thirty-six patients completed the study. Salbutamol was safe and well tolerated. We observed a significant and progressive increase in SMN2 full-length levels in peripheral blood of the salbutamol-treated patients (p<0.00001). The exploratory analysis of motor function showed an improvement in most patients. Conclusions: Our data demonstrate safety and molecular efficacy of salbutamol. We provide the first longitudinal evaluation of SMN levels (both transcripts and protein) in placebo and in response to a compound modulating the gene expression: SMN transcript dosage in peripheral blood is reliable and may be used as pharmacodynamic marker in clinical trials with systemic compounds modifying SMN2levels. Trial registration number: EudraCT no. 2007-001088-32.",
keywords = "double-blind clinical trial, real-time PCR, salbutamol, spinal muscular atrophy",
author = "Tiziano, {Francesco Danilo} and Rosa Lomastro and Emanuela Abiusi and Pasanisi, {Maria Barbara} and {Di Pietro}, Lorena and Stefania Fiori and Giovanni Baranello and Corrado Angelini and Gianni Sorar{\`u} and Alessandra Gaiani and Tiziana Mongini and Liliana Vercelli and Eugenio Mercuri and Gessica Vasco and Marika Pane and Giuseppe Vita and Gianluca Vita and Sonia Messina and Roberta Petillo and Luigia Passamano and Luisa Politano and Angela Campanella and Renato Mantegazza and Lucia Morandi",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/jmedgenet-2018-105482",
language = "English",
journal = "Journal of Medical Genetics",
issn = "0022-2593",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy

T2 - Results of a phase IIb double-blind study of salbutamol

AU - Tiziano, Francesco Danilo

AU - Lomastro, Rosa

AU - Abiusi, Emanuela

AU - Pasanisi, Maria Barbara

AU - Di Pietro, Lorena

AU - Fiori, Stefania

AU - Baranello, Giovanni

AU - Angelini, Corrado

AU - Sorarù, Gianni

AU - Gaiani, Alessandra

AU - Mongini, Tiziana

AU - Vercelli, Liliana

AU - Mercuri, Eugenio

AU - Vasco, Gessica

AU - Pane, Marika

AU - Vita, Giuseppe

AU - Vita, Gianluca

AU - Messina, Sonia

AU - Petillo, Roberta

AU - Passamano, Luigia

AU - Politano, Luisa

AU - Campanella, Angela

AU - Mantegazza, Renato

AU - Morandi, Lucia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, due to the loss of function of the survival motor neuron (SMN1) gene. The first treatment for the condition, recently approved, is based on the reduction of exon 7 skipping in mRNAs produced by a highly homologous gene (SMN2). The primary objective of the present study was to evaluate the applicability of the dosage of SMN gene produts in blood, as biomarker for SMA, and the safety of oral salbutamol, a beta2-adrenergic agonist modulating SMN2 levels. Methods: We have performed a 1-year multicentre, double-blind, placebo-controlled study with salbutamol in 45 adult patients with SMA. Patients assumed 4 mg of salbutamol or placebo/three times a day. Molecular tests were SMN2 copy number, SMN transcript and protein levels. We have also explored the clinical effect, by the outcome measures available at the time of study design. Results: Thirty-six patients completed the study. Salbutamol was safe and well tolerated. We observed a significant and progressive increase in SMN2 full-length levels in peripheral blood of the salbutamol-treated patients (p<0.00001). The exploratory analysis of motor function showed an improvement in most patients. Conclusions: Our data demonstrate safety and molecular efficacy of salbutamol. We provide the first longitudinal evaluation of SMN levels (both transcripts and protein) in placebo and in response to a compound modulating the gene expression: SMN transcript dosage in peripheral blood is reliable and may be used as pharmacodynamic marker in clinical trials with systemic compounds modifying SMN2levels. Trial registration number: EudraCT no. 2007-001088-32.

AB - Background: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder, due to the loss of function of the survival motor neuron (SMN1) gene. The first treatment for the condition, recently approved, is based on the reduction of exon 7 skipping in mRNAs produced by a highly homologous gene (SMN2). The primary objective of the present study was to evaluate the applicability of the dosage of SMN gene produts in blood, as biomarker for SMA, and the safety of oral salbutamol, a beta2-adrenergic agonist modulating SMN2 levels. Methods: We have performed a 1-year multicentre, double-blind, placebo-controlled study with salbutamol in 45 adult patients with SMA. Patients assumed 4 mg of salbutamol or placebo/three times a day. Molecular tests were SMN2 copy number, SMN transcript and protein levels. We have also explored the clinical effect, by the outcome measures available at the time of study design. Results: Thirty-six patients completed the study. Salbutamol was safe and well tolerated. We observed a significant and progressive increase in SMN2 full-length levels in peripheral blood of the salbutamol-treated patients (p<0.00001). The exploratory analysis of motor function showed an improvement in most patients. Conclusions: Our data demonstrate safety and molecular efficacy of salbutamol. We provide the first longitudinal evaluation of SMN levels (both transcripts and protein) in placebo and in response to a compound modulating the gene expression: SMN transcript dosage in peripheral blood is reliable and may be used as pharmacodynamic marker in clinical trials with systemic compounds modifying SMN2levels. Trial registration number: EudraCT no. 2007-001088-32.

KW - double-blind clinical trial

KW - real-time PCR

KW - salbutamol

KW - spinal muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=85059317188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059317188&partnerID=8YFLogxK

U2 - 10.1136/jmedgenet-2018-105482

DO - 10.1136/jmedgenet-2018-105482

M3 - Article

AN - SCOPUS:85059317188

JO - Journal of Medical Genetics

JF - Journal of Medical Genetics

SN - 0022-2593

ER -